Rallybio Corporation
RLYBAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Jones Trading | downgrade | Buy →Hold | Apr 15, 2025 |
| H.C. Wainwright | downgrade | Buy →Neutral | Apr 9, 2025 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Apr 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 30, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 3, 2024 |
| Evercore ISI Group | maintain | Outperform | Aug 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| JP Morgan | downgrade | Overweight →Neutral | May 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 10, 2024 |
| JMP Securities | maintain | Market Outperform | Apr 19, 2024 |
| JMP Securities | maintain | Market Outperform | Apr 18, 2024 |
| Wedbush | maintain | Outperform | Apr 11, 2024 |
| JMP Securities | maintain | Market Outperform | Mar 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2024 |
| Jefferies | downgrade | Buy →Hold | Feb 7, 2024 |
| JMP Securities | maintain | Market Outperform | Feb 7, 2024 |
| Wedbush | maintain | Outperform | Feb 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 7, 2024 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-1.60| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 27, 2026 | $-0.48 | $-1.44 | — | — |
| Aug 6, 2026 | $-1.09 | $-1.28 | — | — |
| May 13, 2026 | $-1.46 | $-1.20 | $212.0K | $212.0K |
| Mar 12, 2026 | $-1.11 | $-1.24 | $222.0K | $100.0K |
| Nov 6, 2025 | $-2.84 | $-1.71 | $212.0K | $66.7K |
| Aug 7, 2025 | $-1.76 | $-1.96 | $212.0K | $66.7K |
| May 8, 2025 | $-1.68 | $-1.68 | $212.0K | $13.3K |
| Mar 13, 2025 | $-2.00 | $-2.16 | $38.0K | $149.5K |
News
Rallybio NASDAQ: RLYB stockholders approved a series of proposals tied to the company's planned merger with Avenzo Therapeutics Inc., including the issuance of Rallybio shares to Avenzo security holders and corporate actions that would take effect in connection with the transaction.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio Corporation (NasdaqCM: RLYB) and Avenzo Therapeutics, Inc. Upon completion of the proposed transaction, pre-Transaction Rallybio equityholders are expected to own approximately 2.8% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, o.
Shares of Rallybio Corporation (NASDAQ: RLYB - Get Free Report) traded up 1.9% during trading on Friday. The stock traded as high as $17.22 and last traded at $17.08. Approximately 7,854 shares changed hands during trading, a decline of 17% from the average session volume of 9,445 shares. The stock had previously closed at $16.76. Wall